Clinical Trials

Regeneron’s Gene Therapy Breakthrough for Hearing Loss
Research & Development Regeneron’s Gene Therapy Breakthrough for Hearing Loss

I'm thrilled to sit down with Ivan Kairatov, a biopharma expert with extensive experience in research and development, particularly in the realm of cutting-edge technologies and innovations in the industry. Today, we’re diving into the groundbreaking world of gene therapy for hearing loss, focusing

Can Serial Biopsies Revolutionize Glioblastoma Treatment?
Research & Development Can Serial Biopsies Revolutionize Glioblastoma Treatment?

What happens when the tools used to fight one of the deadliest cancers fail to tell the full story, and how can a new approach change the game? Glioblastoma, an aggressive brain cancer with a survival rate of less than 15 months for most patients, has long evaded effective treatment, but a

How Do Trump Cuts Impact UC Research and Patient Care?
Research & Development How Do Trump Cuts Impact UC Research and Patient Care?

Imagine a world where life-saving medical research grinds to a halt, not because of a lack of expertise or innovation, but due to political disputes far removed from the lab. This scenario is unfolding across the University of California (UC) system, where federal funding freezes initiated by the

Post-Trial Access: A Critical Compliance Imperative
Research & Development Post-Trial Access: A Critical Compliance Imperative

In the realm of clinical research, the conclusion of a trial often feels like crossing a finish line, with key milestones such as database lock, the final monitoring visit, or the last patient out signaling closure for sponsors and contract research organizations (CROs). However, for the

McMaster Unveils AI-Driven Antibiotic for IBD Treatment
Research & Development McMaster Unveils AI-Driven Antibiotic for IBD Treatment

In a remarkable leap forward for medical science, researchers at McMaster University in Canada have introduced a groundbreaking antibiotic named enterololin , tailored specifically to combat inflammatory bowel disease (IBD), which encompasses debilitating conditions like Crohn's disease. This

Targeting EZH2 to Stop Triple-Negative Breast Cancer Spread
Research & Development Targeting EZH2 to Stop Triple-Negative Breast Cancer Spread

Triple-negative breast cancer (TNBC) remains one of the most formidable challenges in oncology, characterized by its aggressive nature and lack of the three common receptors—estrogen, progesterone, and HER2—that many standard therapies target, leaving patients with limited treatment options and

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later